Evidence map›Paper›PMID 37241759›Full record

ArticleMolecules (Basel, Switzerland)2023

Lingna Xie, Guangrong Liu, Zebin Huang, Zhenyuan Zhu, Kaiye Yang, Yiheng Liang, Yani Xu, Lanyue Zhang, Zhiyun Du

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Journal of hepatocellular carcinoma · 2026
    Article
  5. Recent advances in polysaccharides fromFrontiers in nutrition · 2025
    Review
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Lingna XieSchool of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou 510006, China.
Guangrong LiuInfinitus Company Ltd., 11 Sicheng Road, Tianhe District, Guangzhou 510000, China.
Zebin HuangSchool of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou 510006, China.
Zhenyuan ZhuState Key Laboratory of Food Nutrition and Safety, Tianjin University of Science and Technology, Tianjin 300457, China.ORCID 0000-0001-8016-5240
Kaiye YangInfinitus Company Ltd., 11 Sicheng Road, Tianhe District, Guangzhou 510000, China.
Yiheng LiangSchool of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou 510006, China.
Yani XuSchool of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou 510006, China.
Lanyue ZhangSchool of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou 510006, China.
Zhiyun DuSchool of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou 510006, China.
Guangdong University of Technology · CNInfinitus (China) · CNTianjin University of Science and Technology · CN

Funding

National Natural Science Foundation of China 22178070the Guangdong Provincial Key Laboratory of Plant Resources Biorefinery 2021GDKLPRB02the Project of Rejuvenation of Science and Technology for Mongolia 2021CG0029
6 · The paper itself

Abstract

Anti-tumor activity of

Indexed as

Melanoma, ExperimentalAnimalsApoptosisBasidiomycotaHumansMacrophagesMiceNF-kappa BPolysaccharidesRAW 264.7 CellsNF-kappa BPolysaccharidesB16co-cultureimmunoregulationmacrophagesTremella fuciformis polysaccharide

Identifiers

PMID37241759
PMCPMC10220659
OpenAlexW4376139035

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.